MarketLens

How is VYJUVEK's Commercial Performance Shaping Krystal Biotech's Outlook

6 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What are the Major Headwinds and Tailwinds Shaping the Biotech Sector in 2026

6 months ago

What's Driving Paycom's Recent Performance and Cautious Outlook

5 months ago

What Drove Guardant Health's Q4 2025 Performance and 2026 Outlook

6 months ago

What Drove Lululemon’s Strong Q3 Performance and Upbeat Q4 Outlook

6 months ago

Krystal Biotech: Profitable, Self-Funding, And Loaded With Optionality

Krystal Biotech reported $116.4M VYJUVEK revenue and $56M net income in Q1, driven by operating leverage. The company holds ~$1B cash, self-funding R&D for pipeline candidates KB803 and KB801.

KRYS

Stock News•3 weeks ago

Vertex Gears Up to Report Q2 Earnings: What Can Investors Expect?

Vertex reports Q2 earnings with focus on Trikafta, Alyftrek, Casgevy, and Journavx sales, plus pipeline updates.

VERX

Stock News•1 months ago

These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead

Krystal Biotech and Exelixis have outperformed the market this year, driven by strong sales in underserved therapeutic areas and a niche in the cancer-drug market.

CVS

Stock News•3 months ago

Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Krystal Biotech (KRYS) management discussed operational progress and strategic outlook at the 2026 Bank of America Global Healthcare Conference. The presentation provided investors with updates on the...

KRYS